Enjaymo J Code: J1302

Drug & Product Overview

HCPCS Descriptor Injection, sutimlimab-jome, 10 mg

HCPCS Added Date October 1, 2022

Manufacturer Bioverativ Therapeutics

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution, Concentrate

About Enjaymo

Enjaymo is a medication aligned to the HCPCS J Code: J1302 for billing, pricing, and reimbursement purposes in the United States. This Hematology medication is administered via the intravenous route and manufactured by Bioverativ Therapeutics.

According to CMS Drug Use Information: Sutimlimab is used to treat a certain rare blood disorder (cold agglutinin disease). This disease causes your body's immune system to break down red blood cells, which results in anemia. Sutimlimab works by helping to block the body's breakdown of red blood cells. This effect helps lessen symptoms of anemia (such as tiredness) and may reduce the need for blood transfusions.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
55292-0820-01	Enjaymo	Recordati Rare Diseases, Inc.	110	1100 MG / 22 ML
80203-0347-01	Enjaymo	Bioverativ Therapeutics Inc.	110	1100 MG / 22 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Enjaymo Pricing & Reimbursement

J1302 Private Payer Reimbursement

$19.07 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Enjaymo Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 9.31%

Avg. Days to File 7.5days

Avg. Days to Pay 26.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J1302 claims analytics on FocalPoint →

Enjaymo CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Enjaymo (J1302) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

Enjaymo Medically Unlikely Edits (MUE)

The most billing units of J1302 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

770 units / day

= 7,700 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Enjaymo Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Cold Agglutinin Disease

Drug Class

Classical Complement Pathway Inhibitor [EPC]Classical Complement Pathway Inhibitors [MoA]

Frequently Asked Questions

Is there an available Enjaymo billing and coding guide?

Billing and coding information for Enjaymo can be found through Bioverativ. Visit Here →

Are there any available Enjaymo patient assistance programs?

Enjaymo patient assistance information can be found through Bioverativ. Visit Here →

Where can I find Enjaymo prescribing information?

Enjaymo prescribing information can be found at the link below: Visit Here →

Where can I find Enjaymo side effect information?

Information regarding Enjaymo's side effects can be found at MedlinePlus Visit Here →

Does billing Enjaymo require JZ/JW wastage modifiers?

CMS has identified Enjaymo(J1302) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.